About us

At Akseera Pharma Corp, we aim at providing patients scientifically proven dosage of the Cannabis extract and isolates through appropriate delivery systems by applying a pharmaceutical approach to the use of Cannabis.

This approach addresses one of the greatest challenges in the field of medical marijuana which is ensuring that uniform, stable, consistent doses are administered to patients. Our research operations are based in Canada and India giving us the advantage of world class research quality at a lower cost.

The Akseera Approach

Coalesce the herbal benefits of the Cannabis extract with the science of pharmaceuticals through:

Isolation and extraction of active compounds from Cannabis spp.

Design of effective, safe and uniform dosage delivery systems

Conducting clinical trials to determine safety and efficacy

Target Consumers

Helping patients whose symptoms are not alleviated by existing pharmaceutical products

    Patients Suffering From :

  • Prostate Cancer
  • Inflammatory conditions like Migraines

The Market

The Globe and Mail (April 2016) published market research by Mackie Research Capital Corp. for the medical marijuana market in Canada. They estimate the market size to be at least $2.5 billion in 2020, contingent to the legalization of medical and recreational use.


Strategic Alliances

Akseera aspires to be the first company in the world to manufacture and launch cost effective and high quality Cannabis based pharmaceutical products in India and Canada through strategic alliances with the Nano-medicine Research Group at Institute of Chemical Technology (ICT), Mumbai; Department of Biomedical Physiology and Kinesiology at Simon Fraser University (SFU), Vancouver and Sterkem Pharma Pvt. Ltd., Mumbai